Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2023 | Low-dose emicizumab prophylaxis in patients with severe hemophilia A

Rucha Patil • 26 Jun 2023
ISTH 2023
Hemophilia Non-Malignant Rare Diseases Antibodies Emicizumab

In this video, Rucha Patil, PhD, ICMR-National Institute of Immunohematology, Mumbai, India, discusses the results of a study evaluating the safety and efficacy of low-dose emicizumab prophylaxis in patients with severe hemophilia A. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rucha Patil

1:05
Promising antibodies being explored in hemophilia & a novel diagnostic tool for patients
Rucha Patil • 26 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals